Stocks Health care ACET
NASDAQ · Health careAdicet Bio, Inc. (ACET)
It posted a net loss of $99M. In fiscal 2025 capital spending exceeded operating cash flow by $97M. At June 30, 2026 it held $33.1M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 5, 2026.
Key facts about Adicet Bio, Inc.
- Net worth
- Adicet Bio, Inc. has a market value (market cap) of $28M at the latest share price, and shareholders' equity of $120.1M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Cash flow
- In fiscal 2025 operations used $95.2M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on August 5, 2026 and covers the period to June 30, 2026. Open on SEC EDGAR
- Next earnings report
- Adicet Bio, Inc.'s next report was expected around November 4, 2026 and is not on file with the SEC yet.
What Adicet Bio, Inc. does
Adicet Bio, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker ACET.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | n/a | -$116.8M | -$16.95 | -$97M |
| 2024 | n/a | -$117.1M | -$21.33 | -$93.5M |
| 2023 | n/a | -$142.7M | -$53.08 | -$98.2M |
| 2022 | n/a | -$69.8M | -$27.26 | -$61.5M |
| 2021 | n/a | -$62M | -$32.08 | -$64.1M |
| 2020 | n/a | -$36.7M | -$80.35 | -$42.5M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Latest SEC filings
What Adicet Bio, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- September 28, 2026
- September 8, 2026
- September 1, 2026
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 5, 2026
- August 5, 2026
- June 18, 2026
- May 20, 2026
- May 15, 2026Passive stake changed SCHEDULE 13G/A
- May 13, 2026Form S-8 POS filing S-8 POS
Insider trades
What the people running Adicet Bio, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider trades were reported in the last 90 days.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| April 27, 2026 | Ra Capital Management, L.P.10% owner | Other changeindirect | 250,000 | - |
| April 8, 2026 | Orbimed Advisors LLC10% owner | Soldindirect | 32,523 | $204.6K |
| April 8, 2026 | Orbimed Advisors LLC10% owner | Soldindirect | 40,416 | $263.5K |
| April 7, 2026 | Orbimed Advisors LLC10% owner | Soldindirect | 29,319 | $191.5K |
| April 7, 2026 | Orbimed Advisors LLC10% owner | Soldindirect | 2,400 | $15.3K |
| February 20, 2026 | Ra Capital Management, L.P.10% owner | Boughtindirect | 74,751 | $543.4K |
| February 19, 2026 | Ra Capital Management, L.P.10% owner | Boughtindirect | 74,268 | $535.5K |
| February 18, 2026 | Ra Capital Management, L.P.10% owner | Boughtindirect | 74,577 | $525K |
Who owns ACET
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| RA Capital Management, L.P.13G, passive with 3 related filers | 9.9% | August 14, 2026 |
| Orbimed Advisors LLC13D, may seek influence with 7 related filers | 8.8% | April 10, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 56 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| RA Capital Management, L.P. | 932,624 | -250,000 |
| Orbimed Advisors LLC | 844,787 | -183,157 |
| Franklin Resources Inc | 626,571 | 0 |
| Citadel Advisors LLC | 432,738 | +50,915 |
| Vanguard Capital Management LLC | 343,228 | +6,704 |
| Adage Capital Partners GP, L.L.C. | 274,375 | 0 |
| Renaissance Technologies LLC | 265,945 | +33,354 |
| Stonepine Capital Management, LLC | 245,518 | +23,563 |
| Alyeska Investment Group, L.P. | 203,799 | 0 |
| Schonfeld Strategic Advisors LLC | 195,514 | new |
| Carlyle Group Inc. | 184,295 | 0 |
| NEXTBio Capital Management LP | 157,827 | 0 |
| Two Sigma Investments, LP | 96,839 | +53,733 |
| Geode Capital Management, LLC | 95,634 | -5,501 |
| DAFNA Capital Management LLC | 93,812 | 0 |
| Bridgeway Capital Management, LLC | 85,959 | new |
| Marshall Wace, Llp | 79,488 | new |
| Trexquant Investment LP | 78,002 | +34,336 |
| Jane Street Group, LLC | 70,561 | +33,477 |
| Burkehill Global Management, LP | 62,500 | 0 |
Insiders
5 insiders reported holding 951,022 shares in total, about $2.8M at the last price.
| Holder | Shares |
|---|---|
| Ra Capital Management, L.P.10% owner | 932,624932,624 held indirectly |
| Schor ChenPresident & CEO, Director | 6,820 |
| Harvey Brian NicholasChief Financial Officer | 5,145 |
| Healey DonChief Technology Officer | 3,452 |
| Aftab BlakeChief Scientific Officer | 2,981 |
Questions about ACET
What does Adicet Bio, Inc. do?
Adicet Bio, Inc. is a company in the Health care sector, listed on NASDAQ as ACET. Its shares trade on NASDAQ under the ticker ACET.
What is Adicet Bio, Inc.'s net worth?
Adicet Bio, Inc. has a market value (market cap) of $28M at the latest share price, and shareholders' equity of $120.1M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Adicet Bio, Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $99M.
When did Adicet Bio, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 5, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the investor disclosure from September 28, 2026.
When is Adicet Bio, Inc.'s next earnings report?
Adicet Bio, Inc.'s next report was expected around November 4, 2026 and is not on file with the SEC yet.
Similar companies
Compare ACET with
Follow ACET
Get an email when Adicet Bio, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Adicet Bio, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.